Clinical Trials
47 trialsA Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
National Cancer Institute (NCI)
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Novartis
TALES
University of California, San Francisco
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
PIKALO-1
Eli Lilly and Company
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Adjuvant WIDER
Novartis
INAVO123
Hoffmann-La Roche
KANDELA-302
BeOne Medicines
FASCINATE-N
Fudan University
CAMBRIA-2
AstraZeneca
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
ELEGANT
Stemline Therapeutics, Inc.
CAMERAN
UNC Lineberger Comprehensive Cancer Center
SELECT
Yale University
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
ELEGANCE
Novartis
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
PLUM
University of California, San Francisco
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
EvoPAR-BR01
AstraZeneca
OPERA-02
Olema Pharmaceuticals, Inc.
OMAHA-015
Merck Sharp & Dohme LLC
CAMBRIA-1
AstraZeneca
POWER II
University of Virginia
I-SPY
QuantumLeap Healthcare Collaborative
ALEPRO
Universitaire Ziekenhuizen KU Leuven
IMPULSE
Novartis
AVZO-023-1001
Avenzo Therapeutics, Inc.
DEBRA
NRG Oncology
CHAMELEON
Memorial Sloan Kettering Cancer Center
Study of Letrozole in Recurrent Gliomas
University of Cincinnati
KAT6
Pfizer
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
RaPhLRR
Hoosier Cancer Research Network
LaPemERLA
National Cancer Centre, Singapore
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
RAMP 301
Verastem, Inc.
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
EndoMAP
Alliance Foundation Trials, LLC.
Morpheus-panBC
Hoffmann-La Roche